To help support the growing industry we have built a large-scale GMP manufacturing centre, which through collaborations will help to address the manufacturing challenges faced by therapy developers.
The CGT Catapult manufacturing centre supports the development of new, large-scale manufacturing systems and capabilities, helping you to bring your cell and gene therapies to market.
The CGT Catapult manufacturing centre provides you with a supportive environment to develop your large-scale manufacturing systems, whilst our segregated modules allow you to maintain control of your underlying process.
The licensed GMP-compliant manufacturing centre provides you with the flexibility of your own facility, as well as access to an established supply chain.
1. Ready when you need it
Through collaborations, we support you in developing large-scale manufacturing systems without the need for capital investment or the associated risk of building and licensing your own facility.
As such, the centre can offer an invaluable opportunity for accelerating commercial-scale production.
2. Access established supply chain
The centre’s location enables you to access an established international inbound supply chain in order to support your manufacture. Our effective outbound supply chain, with easy access to Heathrow and major international transport links, also allows you to receive and deliver your therapies to key clinical centres.
The ThermoFisher's CryoHub located at the centre offers a complete cryogenic storage, distribution and logistics solution.
3. Flexible to your needs
The centre is designed to be adaptive to your processing needs, enabling you to freely adjust your manufacturing strategy as you grow, as well as take on more modules and replicate your module design in your own facility.
The flexible module design and supporting infrastructure is conformable to your own process, whether it is allogenic, viral vector or autologous.
4. Control your manufacturing strategy
The centre’s architecturally segregated modules enable you to develop your process while retaining your intellectual property and know-how; the people, process, quality management system, batch release and IP are all yours.
We work with you, from managing core operational and quality assurance activities to letting you focus on developing your processes.
5. Collaborate with industry specialists
The centre is supported by a team of specialists across the cell and gene therapy lifecycle, who work with you diligently when you need them.
The centre has been specifically designed to meet the demands of cell and gene therapy manufacturing. Our adaptive clean room design allows the development of autologous or allogenic manufacturing processes, as well as viral vectors.
In July 2018, the European Regional Development Fund (ERDF) awarded CGT Catapult £3.36m in funding to support the expansion of their manufacturing centre, in order to provide additional support for growing cell and gene therapy companies. The construction of six additional modules in the available space on the building's second floor was completed in September 2019.
The six additional modules contain Grade C cleanrooms allowing the running of closed processes, and each have a production footprint of 130m2. The additional space and support for this project allows CGT Catapult to engage further with UK businesses and accelerate their progress towards commercialisation.
The cell and gene therapy cluster formed around Stevenage is the UK’s largest cell and gene therapy cluster (and third largest globally). It was developed around Stevenage, with the Stevenage Advanced Therapeutics Campus and the CGT Catapult manufacturing centre at the core of the development.
See how the third largest global cell and gene therapy cluster has developed:
Commercial readiness advice clinics
The core of our mission resides in assisting companies to accelerate their product from research status to a viable commercial product. Our commercial readiness advice clinics allow eligible SMEs and spin-out companies to benefit from 12 hours of tailored support in preparation for industrialisation. We provide access to CGT Catapult experts for all product development steps, including: clinical, non-clinical, intellectual property, health economics, market access, manufacturing and industrialisation.
This programme is part funded by the European Regional Development Fund (ERDF).
The cell and gene therapy cluster centered around Stevenage
Click and drag to explore the Stevenage Advanced Therapeutics Campus:
This unique new centre will bring together our expertise in medicines manufacturing with our world-beating science and research base to create revolutionary treatments that fight diseases like cancer and save lives.
This new cell and gene centre represents our ambitious Industrial Strategy in action. By bringing together universities and businesses we can not only create the high value jobs we need but also develop potentially lifesaving treatments.
The Cell and Gene Therapy Catapult manufacturing centre is a crucial component of the industrial strategy and part of the leading-edge healthcare technology challenge fund. This world-leading centre will bring manufacturing of pioneering treatments closer to patients and will complement the new Advanced Therapy Treatment Centres.
European Regional Development Fund
The project has received £3.36m in funding from the England European Regional Development Fund as part of the European Structural and Investment Funds Growth Programme 2014-2020. The Ministry of Housing, Communities and Local Government (in London the intermediate body Greater London Authority) is the Managing Authority for European Regional Development Fund.
Established by the European Union, the European Regional Development Fund helps local areas to stimulate their economic development through investing in projects which support innovation, businesses, create jobs and advance local community regeneration. For more information visit https://www.gov.uk/european-growth-funding.